Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response | Zendy

Peter Kern | Zendy; Anne Kalisch | Zendy; HansChristian Kolberg | Zendy; Rainer Kimmig | Zendy; F Otterbach | Zendy; Gϋnter von Minckwitz | Zendy; William M. Sikov | Zendy; Dirk Pott | Zendy; Christian M. Kurbacher | Zendy

Open Access

Neoadjuvant, Anthracycline-Free Chemotherapy with Carboplatin and Docetaxel in Triple-Negative, Early-Stage Breast Cancer: A Multicentric Analysis of Feasibility and Rates of Pathologic Complete Response

Author(s) -

Peter Kern,

Anne Kalisch,

HansChristian Kolberg,

Rainer Kimmig,

F Otterbach,

Gϋnter von Minckwitz,

William M. Sikov,

Dirk Pott,

Christian M. Kurbacher

Publication year - 2013

Publication title -

chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.539

H-Index - 54

eISSN - 1421-9794

pISSN - 0009-3157

DOI - 10.1159/000362756

Subject(s) - carboplatin , docetaxel , medicine , anthracycline , regimen , taxane , breast cancer , oncology , febrile neutropenia , chemotherapy , triple negative breast cancer , clinical endpoint , neutropenia , surgery , cancer , randomized controlled trial , cisplatin

Triple-negative breast cancer (TNBC) attracts a disproportionate share of intensive research because of its poor prognosis. Standard anthracycline- and taxane-based regimens still yield an unsatisfactorily low rate of pathologic complete response (pCR). The pCR rate is a recognized surrogate marker for good long-term survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research